Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Revenue: 2023-2025

Historic Revenue for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $348,000.

  • NewAmsterdam Pharma Co N.V's Revenue fell 98.80% to $348,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 4.91%. This contributed to the annual value of $45.6 million for FY2024, which is 223.37% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Revenue stood at $348,000 for Q3 2025, which was down 98.18% from $19.1 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Revenue registered a high of $29.1 million during Q3 2024, and its lowest value of $348,000 during Q3 2025.
  • Moreover, its 3-year median value for Revenue was $2.9 million (2023), whereas its average is $7.5 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Revenue soared by 1,490.54% in 2024, and later tumbled by 98.80% in 2025.
  • NewAmsterdam Pharma Co N.V's Revenue (Quarterly) stood at $803,000 in 2023, then skyrocketed by 1,490.54% to $12.8 million in 2024, then tumbled by 98.80% to $348,000 in 2025.
  • Its last three reported values are $348,000 in Q3 2025, $19.1 million for Q2 2025, and $3.0 million during Q1 2025.